The goal of CalciMedica’s development programs is to explore the therapeutic benefits of CRAC (calcium release-activated calcium) channel inhibitors in inflammatory diseases of the pancreas, kidney, lung and other organs.

CalciMedica’s current drug development efforts build on nearly two decades of research into the role of CRAC channels in the immune response as well as preclinical and clinical research demonstrating the potential therapeutic benefit of CRAC channel inhibitors in life-threatening inflammatory diseases. CalciMedica was founded in 2007 by Dr. Ken Stauderman and colleagues from TorreyPines Therapeutics, along with a team from Harvard’s CBR Institute for Biomedical Research. Dr. Stauderman is a world leader in CRAC channel biology and pharmacology.

In 2016, CalciMedica advanced its lead compound, Auxora™, into clinical development. Auxora™, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results and has been well-tolerated in four completed Phase 2 clinical trials. Auxora™ is in development for acute pancreatitis and asparaginase-induced pancreatic toxicity.

CalciMedica, Inc., is focused on further developing Auxora™, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-induced pancreatic toxicity (AIPT), acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS), for which there are no currently approved therapies.

The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic inflammatory conditions.